版本:
中国

BRIEF-Syros announces FDA acceptance of IND to advance SY-1365

April 10 Syros Pharmaceuticals Inc

* Syros announces FDA acceptance of IND to advance SY-1365, its first-in-class selective CDK7 inhibitor, into phase 1 clinical trial in patients with advanced solid tumors

* Syros Pharmaceuticals Inc - company on track to initiate study in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐